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INTRODUCTION 
Neurodegenerative diseases, such as Alzheimer’s and 
Parkinson’s, are associated with aging, and their pre-
valence is increasing as there are more individuals that 
reach  older ages  [1–3].   To  date,  there  are  no curative 
treatments for any of these diseases owing to the fact that 
their molecular origins are still poorly understood. In-
stead, palliative treatments are directed to alleviate down-
stream events, such as beta-amyloid deposition in the case 
of Alzheimer’s or lack of dopamine generation in the case 
of Parkinson’s due to the loss of dopaminergic neurons. 
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ABSTRACT 
Neurodegenerative diseases associated with old age such as Alzheimer’s disease present major problems for 
society, and they currently have no cure.  The telomere protective caps at the ends of chromosomes shorten 
with age, and when they become critically short, they can induce a persistent DNA damage response at 
chromosome ends, triggering secondary cellular responses such as cell death and cellular senescence.  Mice and 
humans with very short telomeres owing to telomerase deficiencies have an earlier onset of pathologies 
associated with loss of the regenerative capacity of tissues.  However, the effects of short telomeres in very low 
proliferative tissues such as the brain have not been thoroughly investigated. Here, we describe a mouse model 
of neurodegeneration owing to presence of short telomeres in the brain as the consequence of telomerase 
deficiency.  Interestingly, we find similar signs of neurodegeneration in very old mice as the consequence of 
physiological mouse aging. Next, we demonstrate that delivery of telomerase gene therapy to the brain of 
these mice results in amelioration of some of these neurodegeneration phenotypes. These findings suggest that 
short telomeres contribute to neurodegeneration diseases with aging and that telomerase activation may have 
a therapeutic value in these diseases. 
www.aging-us.com 2917 AGING 
Telomeres are heterochromatic protective structures at 
the ends of chromosomes that consist of TTAGGG 
repeats bound by a six-protein complex known as 
shelterin [4,5]. A minimum length of telomeric repeats 
is necessary for shelterin binding and protection [4,5]. 
Telomerase is a reverse transcriptase which can 
elongate telomeres de novo by the addition of telomeric 
repeats onto chromosome ends [6], in this manner 
compensating progressive telomere attrition as a conse-
quence of cell division.  Telomerase is composed of two 
essential subunits, the telomerase reverse transcriptase 
(TERT) and the telomerase RNA component (Terc), 
which is used as a template for the synthesis of 
telomeric repeats [6].  Adult tissues, including the stem 
cell compartments, do not have sufficient telomerase 
activity to compensate for telomere shortening 
associated with tissue regeneration and cell division [7–
9]. When telomeres reach a critically short length, this 
triggers activation of a persistent DNA damage 
response at telomeres and the subsequent induction of 
cellular senescence or apoptosis [5,10].  Short/dysfunc-
tional telomeres are considered one of the primary 
hallmarks of aging both in mice and humans, as they 
lead to other hallmarks of aging, such as genomic 
instability, cellular senescence, and loss of the 
regenerative capacity of tissues [11]. In particular, 
critically short telomeres in the stem cell compartments 
lead to impaired tissue renewal and homeostasis [12–
14]. Interestingly, the rate of telomere shortening 
throughout lifespan is influenced by both genetic factors 
(i.e. mutations in genes necessary for telomere 
maintenance) and environmental factors (i.e. cigarette 
smoke has a negative effect) [15,16].  Interestingly, 
there are a number of diseases associated to mutations 
in telomerase and other telomere maintenance genes 
known as “telomere syndromes”, which include 
dyskeratosis congenita, aplastic anemia and pulmonary 
fibrosis, among others (for a review see [17]). These 
syndromes are characterized by the presence of 
extremely short telomeres, which prematurely impair 
the regenerative capacity of tissues, affecting both high 
and low proliferative tissues [17,18]. Prior to the 
discovery of human “telomere syndromes”, similar 
findings were made by studying mice genetically 
modified to lack the telomerase RNA component 
(Terc-/-) [19]. Terc-deficient mice have shorter telo-
meres with increasing mouse generations and this 
results in a progressive decrease of both median and 
maximum longevity [20,21].  These mice show pre-
mature appearance of different pathologies affecting 
both proliferative and non-proliferative tissues, which 
are accompanied by an impaired regenerative capacity 
(reviewed in [10,13]). 
In support of critically short telomeres being a 
determinant of aging and longevity, we previously 
showed that increased TERT expression in the context 
of cancer resistant transgenic mice was sufficient to 
delay aging and extend mouse longevity by 40% [22].  
We further demonstrated that telomerase reactivation 
in adult tissues by using adeno-associated viruses 
(AAV9-Tert) was able to significantly delay age-
related diseases and increase longevity in wild-type 
mice [23].  In particular, AAV9-Tert treatment re-
sulted in reduced age-related osteoporosis, reduced 
glucose intolerance, increased neuromuscular coor-
dination, enhanced memory in an object recognition 
test, improved mitochondrial fitness, and delayed 
cancer, thus demonstrating that telomere shortening is 
causative of aging and is at the origin of a wide range of 
age-associated diseases, including cognitive decline 
[23].  More recently, we have also shown that AAV9-
mediated telomerase activation has therapeutic effects 
in pre-clinical mouse models for diseases associated 
with short telomeres such as aplastic anemia [24], 
myocardial infarction [25], and pulmonary fibrosis 
[26]. 
In spite of the fact that the brain is a low-proliferative 
tissue, there are regenerative areas within the brain such 
as the hippocampus, the subventricular zone (SVZ), and 
the olfactory bulb. Interestingly, several studies suggest 
the presence of short telomeres in patients with 
advanced Alzheimer’s disease [27–32].  In the case of 
Parkinson’s disease, extensive research has not been 
performed.  A few studies have found a correlation 
between short telomere length and Parkinson’s disease 
[33,34], while other studies found no correlation 
[35,36].  These studies were performed with peripheral 
blood leukocytes, and telomere length was not 
measured in the brain cells implicated in Parkinson’s 
disease.  In mice, we have previously shown that telo-
mere attrition in the context of the Terc-deficient mouse 
model [19] impairs in vitro proliferation of adult neural 
stem cells from the SVZ [37], and that telomere 
shortening in mice disrupts neuronal differentiation and 
neurogenesis [38]. These findings pose the interesting 
hypothesis that telomerase reactivation in the brain may 
have significant therapeutic effects. Indeed, both in our 
AAV9-Tert mediated telomerase reactivation model 
[23] and in a genetic Tert reactivation mouse model
[39], there were beneficial effects associated to
telomerase reactivation in the brain.  In particular,
telomerase re-expression in a telomerase-deficient
mouse model with short telomeres, resulted in a larger
brain weight, a thicker myelin sheath, better perfor-
mance in an innate avoidance test as a measure of the
health of the olfactory bulb, and increased molecular
markers of Ki67, Sox2, doublecortin, and Olig2 [39].
Similarly, telomerase re-expression in the brain using
AAV9 gene therapy in adult wild-type mice was
sufficient to improve cognitive function [23].
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Here, we set to evaluate whether mice with short 
telomeres in the brain owing to telomerase deficiency 
could be used as a bona fide neurodegeneration model. 
To this end, we characterized the molecular conse-
quences of the presence of short telomeres in the 
neurogenic areas of the brain as well as the potential 
cognitive defects associated to short telomeres in these 
mice. We also explored whether similar signs of neuro-
degeneration can be found in wild-type mice associated 
to physiological mouse aging. Finally, we demonstrate 
that telomerase activation using AAV9-Tert gene 
therapy can ameliorate the brain phenotypes in these 
mice. 
RESULTS 
Histological and molecular defects associated to 
shorter telomeres in the brain of telomerase-
deficient mice 
First, we set to characterize brain phenotypes in the 
telomerase-deficient Tert-/- mouse model used in this 
study [40–43]. We first weighed the brains of age-
matched wild-type and third generation (G3) Tert-/- 
mice, which have shorter telomeres owing to telomerase 
deficiency for three generations.  We observed that the 
brains of G3 Tert-/- mice showed a tendency to be 
smaller than those of age-matched wild-type controls 
(Figure 1A), in agreement with a previous report [39]. 
A reduced brain size may be indicative of neuro-
degeneration as this phenotype is also observed in 
patients with advanced Alzheimer’s disease [44]. In this 
regard, we quantified the size of the hippocampus and 
dentate gyrus (DG) of the different mouse cohorts 
(Figure 1B).  We found that G3 Tert-/- mice also show 
smaller hippocampus and dentate gyrus regions than 
wild-type mice (Figure 1B). 
We next set to characterize the molecular events 
associated to telomerase deficiency in the brain of G3 
Tert-/- mice.  We first determined telomere length in 
several brain regions of age-matched wild-type and G3 
Tert-/- mice, including the hippocampus since this 
structure is critical for learning, memory, memory for 
episodic events, and neurogenesis [45,46], as well as the 
DG area within the hippocampus since this region is 
involved in neurogenesis [47–51] (see scheme in Figure 
1C). In addition, we also studied telomere length in the 
subventricular zone which is important for neurogenesis 
in the adult brain [52], and the neocortex which is 
important for higher-order brain functions such as 
sensory perception, cognition, generation of motor 
commands, spatial reasoning, and language [53]. To this 
end, we performed quantitative telomere FISH (Q-
FISH) directly on coronal paraffin brain sections from 
young wild-type (8-10-weeks old), old wild-type (71-
weeks old), young G3 Tert-/- (14-weeks old), and old G3 
Tert-/- mice (69-72-weeks old). We found that telomeres 
were significantly shorter in the hippocampus, dentate 
gyrus, subventricular zone, and neocortex of G3 Tert-/- 
mice compared to the same regions in wild-type mice 
(Figure 1C-F).  Accordingly, we also found that the 
percentage of short telomeres in G3 Tert-/- in these brain 
regions was higher (Figure 1C-F).  Short telomeres 
were defined as telomeres with a fluorescence intensity 
less than the 15th percentile of the intensity values of a 
control. 
Next, we determined whether shorter telomeres in these 
brain regions of Tert-/- mice were associated to reduced 
proliferation and increased DNA damage [54].  To this 
end, we used immunohistochemistry to determine the 
number of Ki67-positive cells as a marker of cycling 
cells and the number of cells positive for γH2AX as a 
marker for DNA damage. In the case of wild-type mice, 
we observed significantly fewer Ki67-positive cells in 
older mice (71-weeks old) compared to younger ages 
(8-weeks old) in the hippocampus, the dentate gyrus, 
subventricular zone (SVZ) of the lateral ventricle 
anterior to the hippocampus level, and the neocortex 
(Figure 2A-C).  Interestingly, young G3 Tert-/- mice 
(14-weeks old) also showed lower numbers of Ki67-
positive cells than age-matched wild-type controls in 
these brain regions, and this was further reduced in the 
old G3 Tert-/- mice (Figure 2A-C).  Regarding DNA 
damage, we found increased numbers of γH2AX-
positive cells in the hippocampus, dentate gyrus, and 
SVZ of old wild-type mice (71-weeks old) compared to 
young mice (8-weeks old) (Figure 2D,E).  Young G3 
Tert-/- mice also showed significantly lower numbers of 
γH2AX-positive cells in the hippocampus, dentate 
gyrus, and subventricular zone compared to older G3 
Tert-/- mice (Figure 2D,E). In the neocortex, more 
γH2AX associated DNA damage was only observed in 
the old G3 Tert-/- mice (Figure 2F).  These results 
indicate that physiological aging in wild-type mice, as 
well as accelerated telomere shortening as a conse-
quence of telomerase-deficiency in the Tert-/- mice, lead 
to decreased proliferation and increased DNA damage in 
the hippocampus, dentate gyrus, SVZ, and neocortex. 
Next, we set to address the impact of shorter telomeres 
on neurogenesis, inflammation, and formation of tau 
protein aggregations. In this regard, neurogenesis has 
been suggested to act as a brain repair mechanism which 
could mitigate the effects of neurodegeneration that 
occurs with Alzheimer’s disease and possibly aging 
[54,55]. Doublecortin is expressed in developing neurons 
and it is considered a bona fide marker of neurogenesis 
[39,56]. To this end, we set to study the expression of 
doublecortin in various brain regions of both wild-type 
and G3 Tert-/- mice. We  found  that the number of  cells 














and G3 Tert-/- mice. We found that the number of cells 
expressing doublecortin was significantly decreased in  
Figure 1. Mice deficient for telomerase have smaller brains, shorter telomeres, more proliferation, more DNA damage, and 
less neurogenesis.  (A) Brain weight and representative images of young and old wild-type and G3 Tert-/- mice.  (B) Area of hippocampus 
and dentate gyrus in untreated mice quantified from representative images of brain sections stained with hematoxylin and eosin. (C) Q-
FISH for telomere spot fluorescence measured in the hippocampus, (D) the dentate gyrus specifically, (E) the subventricular zone, and (F) 
the neocortex.  The mean telomere spot fluorescence is shown.  The percentage of short telomeres is also shown with “short” being 
defined as a fluorescence intensity less than the 15th percentile of the fluorescence intensity values of a control sample.  Cartoon diagrams 
label the different regions of the brain.  In part (C), A scan of a coronal brain cross section without fluorescence is shown with the 
hippocampus region highlighted in yellow.  Representative images show the telomere spots labeled with Cy3-Tel probe (in red), and nuclei
stained with DAPI (blue). 






Figure 2.  Immunohistochemistry of Ki67 and γH2AX in the brain. (A-F) The quantification and representative images of the 
immunohistochemistry for positive cells per field of view for (A-C) Ki67, and (D-F) γH2AX in brain regions such as the hippocampus, dentate 
gyrus, subventricular zone (SVZ) of the lateral ventricle anterior to the hippocampus level, and the neocortex.  The data is shown for young 
and old wild-type and G3 Tert-/- mice. Data represent the mean ±SE of analyzed mice within each group. For the histopathology results, the 
number of mice analyzed per group is indicated, as well as the number of fields of view, and the number of positive cells. The t-test was 
used for statistical analysis. *p<0.05; **p<0.01; ***p<0.001. 
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expressing doublecortin was significantly decreased in 
old wild-type mice (71-weeks old) compared to young 
(8-weeks old) wild-type mice in the hippocampus and 
the SVZ, and showed the same tendency in the dentate 
gyrus and the neocortex (Figure 3A-C).  Young G3 
Tert-/- mice also showed lower numbers of cells ex-
pressing doublecortin in the hippocampus, dentate 
gyrus, subventricular zone, and neocortex compared to 
age-matched wild-type controls, and this was further 
aggravated with increasing age (Figure 3A-C).  The 
same trends were observed for doublecortin expression 
in the parietotemporal region of the cerebral cortex 
(Figure S1A), and the occipital region of the cerebral 
cortex (Figure S1B).  Neurogenic niches were also 
identified in hematoxylin and eosin stains in the parietal 
subventricular zone area, and the young wild-type mice 
had higher levels of neurogenic niches than old wild-
type mice (Figure S1C).  In agreement with this finding, 
young G3 Tert-/- mice had more neurogenic niches than 
old G3 Tert-/- mice, but less than young wild-type mice 
(Figure S1C).  These findings indicate that shorter 
telomeres associated with aging and to telomerase-
deficiency correlate with impaired neurogenesis in 
different regions of the brain. 
A sign of brain aging is neuroinflammation [57]. In 
particular, the expression of glial fibrillary acidic 
protein (GFAP) by astrocytes increases with aging as 
astrogliosis and neuroinflammation occurs, and such an 
increase is also observed in mouse models with in-
creased neuroinflammation [58–60].  The increase in 
GFAP expression accompanies increased expression of 
inflammatory cytokines, accumulation of proteotoxic 
aggregates, and senescence [58].  To address, whether 
physiological aging and/or short telomeres in the 
context of telomerase deficiency lead to increased 
inflammation in the brain, we measured the number of 
immune astrocyte cells with strong expression of the 
GFAP marker [61]. We observed that young wild-type 
mice have low levels of GFAP in the hippocampus and 
dentate gyrus, whereas old wild-type, young G3 Tert-/-, 
and old G3 Tert-/- mice have more GFAP-positive 
astrocytes in these areas (Figure 3D). We did not find 
significantly more GFAP in the neocortex of G3 Tert-/-
mice compared to wild-type, but did find an increase of 
GFAP with age in both generations (Figure 3E). 
Another sign of brain aging is the accumulation of tau or 
abnormal phosphorylation of tau protein located 
throughout the brain in various cell types such as neu-
rons, astrocytes, and oligodendrocytes, ultimately 
resulting in aggregates and neurofibrillary tangles [62–
64] . Indeed, tau has been associated with Alzheimer’s
because hyperphosphorylation of tau results in loss of its
biological activity [65].  To address this in our mouse
models, we measured protein aggregation by determining
the number of cells positive for tau phosphorylated at 
serine 396 [66,67]. We observed more cells positive for 
phosphorylated tau in the hippocampus and dentate gyrus 
of old wild-type mice, and this effect was further 
increased in old G3 Tert-/- mice (Figure 3F). 
In summary, these findings indicate that short telomeres 
in the brain contribute to impair brain neurogenesis and 
to increase neuroinflammation and abnormal tau phos-
phorylation. Interestingly, similar phenotypes were 
observed associated to physiological aging in very old 
wild-type mice. 
Telomerase-deficient mice are more susceptible to 
MPTP neurotoxin 
To determine whether mice deficient for telomerase 
were more susceptible to cellular damage, we per-
formed an experiment with the MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) neurotoxin.  MPTP 
specifically damages dopaminergic neurons in the 
substantia nigra region of the brain [68].  Inside these 
neurons, MPTP is metabolized to MPP+ which then 
interferes with complex I of the electron transport chain 
in mitochondria, ultimately resulting in oxidative 
damage.  The MPTP neurotoxin model is a common 
model used to study Parkinson’s disease [69].  In our 
experiment, 12-16-week old male wild-type and G3 
Tert-/- mice were injected IP (intraperitoneally) with 0.5, 
5, 10, or 20 mg/kg MPTP and sacrificed 7 days later 
(scheme in Figure S2A).  An additional injection was 
administered 2 hours later since multiple injections have 
been suggested by previous protocols [69].  A footprint 
test resulted in a trend showing that wild-type and G3 
Tert-/- mice injected with the MPTP had a shorter hind 
paw stride length (Figure S2B).  In addition, we per-
formed a tail suspension test to measure mobility. In 
particular, we hung the mice from the tail for a period of 
5 min and measured their immobility time. Mice that 
are old, unhealthy, or more depressed, move less in the 
tail suspension test [70].  We found that wild-type mice 
exhibited a shorter immobility time than MPTP-treated 
wild-type and G3 Tert-/- mice (Figure S2C).  After 7 
days, the mice were sacrificed, and the brain was 
preserved with formalin.  In order to investigate the 
dopaminergic neurons, we performed an immuno-
fluorescence experiment for the tyrosine hydroxylase 
marker.  Tyrosine hydroxylase is important in dopami-
nergic neurons since it converts the amino acid L-
tyrosine to L-DOPA which is a precursor for dopamine 
[71].  We found that 12-16-week old male mice injected 
with higher doses of MPTP had lower levels of tyrosine 
hydroxylase (Figure S2D).  Interestingly, saline-treated 
control G3 Tert-/- mice showed less tyrosine hydro-
xylase than wild-type mice (Figure S2D), and G3 Tert-/- 
mice treated with a low dose of MPTP  showed  less ty- 









Figure 3.  Immunohistochemistry of doublecortin, GFAP, and tau in the brain.  (A-F) The quantification and representative 
images of the immunohistochemistry for positive cells per field of view for (A-C) doublecortin, (D-E) glial fibrillary acidic protein (GFAP), and 
(F) p-Tau(Ser396) in brain regions such as the hippocampus, dentate gyrus, and the neocortex.  The data is shown for young and old wild-
type and G3 Tert-/- mice. Data represent the mean ±SE of analyzed mice within each group. For the histopathology results, the number of
mice analyzed per group is indicated, as well as the number of fields of view, and the number of positive cells. The t-test was used for 
statistical analysis. *p<0.05; **p<0.01; ***p<0.001.
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rosine hydroxylase than similarly treated wild-type mice 
(Figure S2D).  
Additionally, old wild-type and old G3 Tert-/- mice had 
lower levels of tyrosine hydroxylase than young mice 
(Figure S2E).  Together these results suggest that G3 
Tert-/- mice are more susceptible to damage to 
dopaminergic neurons in the substantia nigra due to 
MPTP neurotoxin, and this damage results in decreased 
mobility. 
Behavioral defects associated to shorter telomeres in 
the brain of telomerase-deficient mice 
We previously showed that old wild-type mice perform 
more poorly than young mice in tests such as the object 
recognition test, rotarod test, and tightrope test [23], 
suggesting a negative impact of telomere shortening 
associated with aging in these tests.  Thus, we here set 
to address whether telomerase deficient mice performed 
more poorly than age-matched wild-type controls in 
different behavioral and cognitive tests. The tightrope 
test measures the ability of mice to balance on a 
tightrope, and the rotarod test measures neuromuscular 
coordination while running on a rotating rod. In 
addition, we performed a tail suspension test to measure 
mobility as described previously in this text. We found 
that late generation G1, G2, G3, and G4 Tert-/- mice 
performed worse than age-matched wild-type mice in 
the tightrope test and rotarod test at older ages (Figure 
S3A,B).  Furthermore, we found that older G2 Tert-/- 
mice are immobile in the tail suspension test for longer 
periods of time than age-matched wild-type mice and 
this was further aggravated in the G3 and G4 Tert-/- 
mice (Figure S3C), suggesting a negative impact of 
progressively shorter telomeres in this test.  Thus, 
telomerase deficiency and shorter telomeres lead to 
significantly impaired performance in several tests that 
measure neuromuscular coordination and balance. 
To further assess a potential impact of telomerase 
deficiency on cognitive function, we subjected the 
different mouse cohorts to an object recognition test. 
We found that G4 Tert-/- mice spent less time 
investigating a novel object in their environment than 
age-matched wild-type mice (Figure S3D), which is an 
indication of poor memory in G4 Tert-/- mice with 
shorter telomeres [72].  Together, these findings indi-
cate that mice with shorter telomeres show noticeable 
behavioral phenotypes consisting of a poorer per-
formance in behavioral and cognitive tests. 
Finally, we set to analyze the brain metabolic activity in 
the different mouse cohorts as another indication of 
brain defects in these mice. To this end, we compared 
differences in metabolic activity in the brains of wild-
type and G3 Tert-/- mice by using positron emission 
tomography (PET) to detect fluorodeoxyglucose (FDG) 
in the brain after injection.  Brain glucose metabolism 
has been found to decrease in human patients with 
Alzheimer’s disease and during senile dementia [73–
75].  We found that G3 Tert-/- mice had a lower standard 
glucose uptake value (SUV) in the brain compared to 
wild-type brains, which is an indication of lower 
metabolic activity (Figure S3E).  The weights of the 
mice were taken into account when calculating the 
SUV. Thus, telomerase deficiency and shorter telomeres 
resulted in decreased glucose metabolism in the brain, 
which is associated with poorer cognitive performance 
and increased neurodegeneration.  
Together, these findings show that Tert-/- mice with 
short telomeres exhibit more neurodegeneration than 
wild-type mice, suggesting an impact of telomere length 
on brain aging in mice. 
AAV9-mediated telomerase transduction of mouse 
brains 
Next, we set to study whether expression of telomerase 
in these mouse models could ameliorate the signs of 
neurodegeneration described above. Previous reports 
have shown that adeno associated viruses of the 
serotype 9 (AAV9) are able to cross the blood brain 
barrier and transduce a significant percentage of cells 
[76–84].  To verify whether in our experimental setting 
an IV (intravenous) injection of the AAV9 vector could 
cause effective expression of the Tert transgene in the 
brain, we injected 8-week old mice with the AAV9-
CMV-Tert, AAV9-CMV-eGFP, or AAV9-CAG-eGFP 
vector, and the mice were sacrificed after 2 weeks of 
treatment to study expression of the eGFP or Tert 
transgenes (scheme in Figure 4A). The “CMV” 
abbreviation corresponds to the cytomegalovirus 
promoter, and the “CAG” abbreviation corresponds to 
the high-expression synthetic CAG promoter [85].  We 
first determined whether AAV9 carrying either eGFP or 
Tert genes caused gene expression in the mouse brain 
upon intravenous (IV) injection in the tail with a dose of 
2E12 viral genomes (vg) per mouse (see Methods).  To 
this end, 8-week old mice were injected with AAV9 
virus particles containing either Tert or eGFP (Figure 
4A) and under either the CMV promoter [23–25], or the 
CAG promoter.  Mice treated with the different viral 
vectors were sacrificed 2 weeks after tail injection and 
several different analyses were performed. We 
performed quantitative qPCR to detect Tert and eGFP 
mRNA expression in the brain (Figure 4B).  We found 
expression of the eGFP gene in the brains of AAV9-
eGFP treated mice but not in brains from the AAV9-
Tert treated mice (Figure 4B). In turn, the Tert  mRNA 
was only  detected  in  the brain  of  AAV9-Tert  treated 







Figure 4.  Experiment scheme and confirmation of virus transduction in the brain.  (A) Scheme of the gene therapy experiment.  
Wild-type mice (8-week old) were injected IV with AAV9-CMV-Tert, AAV9-CMV-eGFP, or AAV9-CAG-eGFP, and sacrificed 2 weeks after 
injection.   (B)  Level of eGFP and Tert mRNA relative to actin in the brain as measured by qPCR 2 weeks post IV tail injection with 2E12 vg of 
AAV9-CMV-Tert, AAV9-CMV-eGFP, AAV9-CAG-eGFP, or no virus.  (C) Quantification and representative images of fluorescence as measured 
by an IVIS instrument in the body and brain of wild-type mice and mice injected IV in the tail with AAV9-CMV-eGFP.  (D)  Quantification and 
representative images of eGFP positive cells in the brain as measured by immunohistochemistry in mice injected in the tail with 2E12 vg 
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mice but not in those treated with AAV9-eGFP (Figure 
4B). We also measured eGFP fluorescence in the whole 
mouse, including the brain, using an IVIS instrument 
(Figure 4C).  AAV9-eGFP treated mice displayed 
detectable eGFP fluorescence in the body as well as in 
the brain, whereas untreated wild-type control mice 
only displayed background levels of fluorescence 
(Figure 4C). Thus, these results confirmed that AAV9 
viruses carrying either the eGFP or Tert genes were 
able to cross the blood-brain barrier and infect cells in 
the brain.  
Note that the AAV9-CMV-eGFP virus should infect the 
same number of cells as the AAV9-CAG-eGFP since 
the viral capsid is the same.  However, the CMV 
promoter results in lower levels of expression, and 
therefore we are unable to detect the AAV9-CMV-
eGFP infected cells by immunohistochemistry or immu-
nofluorescence.  Therefore, the AAV9-CAG-eGFP 
vector was utilized to locate infected cells and determine 
the number of cells that were infected.  We could not use 
an AAV9-CAG-Tert vector because the genetic material 
is too large to efficiently pack into the viral vector.   
Next, in order to visualize eGFP expression in different 
brain areas by immunohistochemistry and immuno-
fluorescence, we used the AAV9-CAG-eGFP vector, 
previously shown to have a very high expression level 
in the brain ([86,87]; see also Figure 4C).  Upon tail 
injection, of AAV9-CAG-eGFP vectors, we used 
immunohistochemistry to detect eGFP positive cells 
throughout the entire brain, including the dentate gyrus, 
CA1 of the hippocampus, CA3 of the hippocampus, 
subventricular zone (SVZ) of the lateral ventricle, the 
neocortex, and the thalamus, which showed the highest 
eGFP expression (Figure 4D). Transduction of brain 
cells was also confirmed by immunofluorescence using 
an antibody against GFP, including all the brain areas 
studied (Figure 4E).  We observed that the transduction 
efficiency of all cells in a whole brain cross-section 
from a position in the brain at the hippocampus level 
was approximately 2.5% as detected by 








0.4% as detected by immunofluorescence (Figure 4E). 
This provides a range for the transduction efficiency 
which is in approximately the same range reported by 
other studies using different promoters [77,88].  We 
also addressed whether AAV9 transduced microglia 
which express the marker Iba1. However, we did not 
detect significant eGFP expression in the Iba1-positive 
microglia cells, also in agreement with previous reports 
[77,89]. 
Next, to address whether telomerase over-expression in 
the adult brain of mice could ameliorate signs of brain 
damage and neurodegeneration in mice, age-matched 
(27-30-weeks of age) wild-type, G3 Tert-/-, and G4 
Tert-/- mice were treated with an IV tail injection of 
2E12 vg of AAV9-Tert or AAV9-null vectors (scheme 
in Figure 4F).  The mice were then followed throughout 
their lifespan until they reached the humane endpoint at 
which time we performed a number of molecular 
determinations.  First, and in agreement with transduc-
tion of mouse brain, qPCR analysis demonstrated 
increased Tert mRNA expression in the brains of mice 
transduced with the AAV9-Tert vectors compared to 
those transduced with the null-vectors at the time of 
death (Figure 4G). Thus, increased Tert expression was 
maintained throughout the lifespan of the mice even 
until the humane endpoint. A graph of the body weights 
of the mice is presented in Figure S4. 
AAV9-Tert gene therapy results in less signs of 
molecular aging in the brain in mice 
First, we assessed the presence of DNA damage at the 
humane endpoint using the γH2AX marker. We 
confirmed more cells with DNA damage with increasing 
Tert-/- generations compared to wild-type mice in the 
hippocampus, the dentate gyrus, and the neocortex of 
mice treated with AAV9-null vectors (Figure 5A,B). 
Interestingly, we observed significantly lower numbers 
of cells with DNA damage for wild-type, G3 Tert-/-, and 
G4 Tert-/- mice groups treated with AAV9-Tert in the 
hippocampus, dentate gyrus, and neocortex compared to 
the controls treated with the AAV9-null vectors (Figure  
AAV9-CAG-eGFP or no virus.  The percentage of eGFP positive cells was calculated from the whole coronal brain cross-section.  The 
representative images show multiple regions throughout the brain as labelled.  (E)  Quantification and representative images of eGFP 
positive cells in the brain as measured by immunofluorescence in mice injected IV in the tail with 2E12 vg AAV9-CMV-eGFP, AAV9-CAG-
eGFP, or no virus.  The percentage of eGFP positive cells was calculated from the whole coronal brain cross-section.  The representative 
images show multiple regions throughout the brain as labelled with DAPI stained nuclei in blue, eGFP in green, and Iba1 for microglia in red.  
(F) Scheme of experiment with injection of AAV9-Tert into young mice.  The mice (wild-type, G3 Tert-/-, and G4 Tert-/- mice) were treated at
a young age (27-30 weeks) by the IV tail injection of 2E12 vg of AAV9-Tert or AAV9-null virus.  (G) The mRNA level of Tert in the brain at the 
humane endpoint.  The mRNA level was measured by qPCR relative to GAPDH.  The ages of the mice as well as the number of weeks of 
treatment for each group are indicated above the graph.  Data represent the mean ±SE of analyzed mice within each group. The number of 
mice analyzed per group is indicated. The t-test was used for statistical analysis. *p<0.05; **p<0.01.
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5A,B).  We also observed reduced levels of the senes-
cence and DNA damage marker Trp53 mRNA in the 
AAV9-Tert treated G4 Tert-/- mice compared to the 




















































ing less DNA damage in the telomerase-treated brains. 
We also addressed whether telomerase treatment had 
any impact on the regenerative neurons of the brain by 






Figure 5. Treatment with AAV9-Tert results in less DNA damage in the brain.  (A-B) Quantification and representative images of 
the histopathology for γH2AX in the (A) hippocampus, (A) dentate gyrus, and (B) neocortex for the cohort of mice (wild-type, G3 Tert-/-, and 
G4 Tert-/- mice) injected with 2E12 vg of AAV9-Tert or AAV9-null.  (C) The level of Trp53 mRNA in the brain as measured by qPCR relative to 
GAPDH at the humane endpoint.  Data represent the mean ±SE of analyzed mice within each group. The number of mice analyzed per 
group is indicated. The t-test was used for statistical analysis. *p<0.05; **p<0.01; ***p<0.001. 







Figure 6. Treatment with AAV9-Tert results in more neurogenesis and less inflammation in the brain.  (A-B) Quantification and 
representative images of the histopathology for doublecortin in the hippocampus (A), dentate gyrus (A), and neocortex (B).  (C) 
Immunofluorescence of tyrosine hydroxylase in the substantia nigra. (D-E) Quantification and representative images of the histopathology 
for glial fibrillary acidic protein (GFAP) in the hippocampus (D), dentate gyrus (D), and (E) neocortex. Data represent the mean ±SE of 
analyzed mice within each group. The number of mice analyzed per group is indicated. The t-test was used for statistical analysis. *p<0.05; 
**p<0.01; ***p<0.001. 
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doublecortin (Figure 6A,B).  As expected, in the AAV9-
null treated controls, we found significantly lower 
numbers of cells positive for doublecortin in the hippo-
campus and dentate gyrus of G4 Tert-/- mice compared to 
the wild-type mice (Figure 6A,B).  Interestingly, AAV9-
Tert treatment resulted in significantly increased numbers 
of doublecortin-positive cells in the hippocampus, the 
dentate gyrus, and the neocortex in G4 Tert-/- mice 
compared to those treated with AAV9-null vectors 
(Figure 6A,B).  Differences were not observed between 
the wild-type groups, which died at a very old age 
(Figure 6A,B).  
We next evaluated dopaminergic neurons responsible 
for motor control and important in Parkinson’s disease 
by quantifying the tyrosine hydroxylase marker (Figure 
6C).  We found that G3 Tert-/- mice treated with AAV9-
Tert had a higher intensity of tyrosine hydroxylase 
fluorescence than those treated with the AAV9-null 
vector (Figure 6C). 
Finally, we determined the number of GFAP-positive 
cells which is indicative of neuroinflammation.  We 
found significantly lower levels of cells positive for 
GFAP in the hippocampus, dentate gyrus, and neocortex 
in G3 Tert-/- mice treated with the AAV9-Tert virus 
compared to the AAV9-null treated controls (Figure 
6D,E).  Thus, the AAV9-Tert therapy shows a trend 
towards reducing the level of inflammation in the brain, 
which reaches statistical significance between some of 
the groups. 
In summary, the fact that we observed fewer cells with 
DNA damage, higher levels of neurogenesis, less 
inflammation, and more tyrosine hydroxylase in dopa-
minergic neurons indicates that the AAV9-Tert gene 
therapy had an impact on these molecular markers of 
aging in the brain. 
AAV9-Tert gene therapy has beneficial effects on 
memory   
In order to assess whether telomerase treatment had any 
impact on brain function, we measured the memory of 
the mice using the Barnes maze test [90].  In the Barnes 
maze test, mice are placed onto a table with 20 holes 
around the edge.  Only one of the holes contains a box 
which the mice can enter.  The mice try to escape the 
aversive stimulus of a wide-open space where they are 
exposed, and they try to find and enter the goal box for 
safety.  The mice are first guided to the location of the 
box with a glass beaker on the first habituation day. 
They are then allowed to find the box on their own for 
several trials for two training days.  After this there is 
one day of rest, and then the performance of the mice is 
measured on the final test day.  At 30 weeks of treat-
ment, the performance of most of the AAV9-Tert 
groups was better than the performance of the corres-
ponding AAV9-null groups (Figure 7).  The number of 
holes that the mice searched before finding the goal box 
is shown in Figure 7A.  A chi-squared test showed that 
the mice treated with AAV9-Tert required less time to 
find the goal box hidden beneath one of the 20 holes on 
the outer edge of the table compared with the 
corresponding AAV9-null treated controls (Figure 7B).  
The graphs for the path length used to find the goal box 
(Figure 7C), the percent of the holes searched in the 
target quadrant of the table (Figure 7D), and the percent 
time spent searching in the target quadrant (Figure 7E) 
are also shown.  Additionally, G3 and G4 Tert-/- mice 
performed more poorly in this Barnes maze test than the 
wild-type controls.  We also constructed representative 
paths taken by the mice in different treatment groups 
(Figure 7F).  These paths were obtained from videos of 
the mice performing the test (Figure 7F).  In order to 
address statistical significance in this test for behavior 
and memory, a chi-squared test was performed by 
counting the number of AAV9-Tert test trials in which 
the value was better than the average value for the 
corresponding AAV9-null group of the same generation.  
These counts were compared to the number of trials that 
would be expected to be better by chance if the AAV9-
Tert therapy had no effect, which is half of the total 
number of trials (Table 1).  The p-value from this chi-
squared test for the time variable was significant with a 
value of 0.00876, in agreement with the fact that nearly 
all the AAV9-Tert trials had a better value than the 
corresponding AAV9-null group average value, with a 
few exception trials.  A similar chi-squared test also 
showed that younger AAV9-null mice (approximately 
30-week old mice after 4 weeks from the injection with 
the AAV9-null virus) performed better than older 
AAV9-null mice (approximately 60-week old mice after 
30 weeks from the injection with the AAV9-null virus) 
as shown in Table 2, supporting the fact that neuro-
degeneration naturally occurs with age. 
DISCUSSION 
Mouse models of Parkinson’s and Alzheimer’s disease 
have been generated in the past, however, many of these 
mouse models have failed to reproduce the complexity 
of the human pathologies [69,91–93], most likely 
because these diseases are normally associated with 
aging, and the aging process may not have been fully 
modeled in the tested mouse models.  One of the 
hallmarks of aging is the progressive shortening of 
telomeres, which are the end-capping structures of 
chromosomes and essential for chromosomal stability 
[11].  When telomeres reach a critically short length this 
is sufficient to trigger a persistent DNA damage 
response, and to trigger cellular senescence and/or 
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apoptosis [94]. Short telomeres also impair the ability of 
stem cells to regenerate tissues, thus contributing to 
tissue aging [12,13]. Here, we set to test whether a 
mouse model of premature aging owing to the presence 
of short telomeres showed signs of molecular brain 
aging similar to those that occur with physiological 
aging. In this regard, we describe here that wild-type 
mice show signs of neurodegeneration with aging and 
that these signs are anticipated in the context of the 
telomerase-deficient mouse model. These findings 
suggest that telomere shortening may be one of the 
determinants of brain aging. Future studies warrant 
analysis of telomere length in other models of Alzhei-
mer’s disease, such as including the APP/PS1 mouse 
model, expressing mutated amyloid precursor protein 
(APP)  and mutated  presenilin  (PS1) [95],  the  SAMP8  
 
 
(Senescence Accelerated Mouse-Prone 8) mouse model 
[96], which exhibits features of accelerated aging, signs  
of neurodegeneration at an early age, and poor perfor-
mance in memory tests [96], or in mice injected with 
amyloid beta peptide, which induces cognitive defects 
[97].  In particular, the increased inflammation often 
observed in these mouse models, may lead to the 
proliferative exhaustion of immune cells in the brain 
such as microglia, and ultimately shorter telomeres. 
Here, we observed increased neurodegeneration with age 
in both old wild-type mice and in G3 Tert-/- mice with 
short telomeres.  Indeed, old age is the main risk factor 
for many diseases, including neurodegenerative diseases 
[98–100].  Telomerase-deficient G3 Tert-/- mice had 
smaller brains and shorter telomeres in the brain, 
and this was coincidental with increased brain aging  as 
 Figure 7. Treatment with AAV9-Tert improves memory in the Barnes maze test. (A-E) Quantification of the performance in the Barnes maze test after 30 weeks of treatment for (A) number of holes searched before reaching the goal box, (B) time required to reach the 
goal box, (C) path length used to reach the goal box, (D) the percent of holes searched in the target quadrant, and (E) the percent time 
spent searching in the target quadrant.  (F) Representative paths of the mice on the Barnes maze table after 30 weeks of treatment.     Data 
represent the mean ±SE of analyzed mice within each group. The number of mice analyzed per group is indicated. 
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indicated by a number of molecular markers.  In some 
instances, however, the differences between wild-type 
and the G3 Tert-/- mice were lost at old ages.  A 





















































tion in these markers already reached the maximum or 
minimum level at older ages, and therefore a 
difference between the wild-type and G3 Tert-/- mice 



















Table 1. Barnes maze chi-squared analysis: Comparison of AAV9-Tert and AAV9-null mice 30 weeks after 
treatment. 
Number of holes searched 
Group Number of Mice Total trials 
Trials with performance 
better than corresponding 




WT AAV9-Tert 5 15 5 7.5 Chi-squared 
p-value
0.109
G3 Tert-/- AAV9-Tert 5 14 12 7 
G4 Tert-/- AAV9-Tert 5 15 7 7.5 
Time 
Group Number of Mice Total trials 
Trials with performance 
better than corresponding 




WT AAV9-Tert 5 15 6 7.5 **Chi-squared 
p-value
0.00876
G3 Tert-/- AAV9-Tert 5 14 13 7 
G4 Tert-/- AAV9-Tert 5 15 13 7.5 
Path length 
Group Number of Mice Total trials 
Trials with performance 
better than corresponding 




WT AAV9-Tert 5 15 9 7.5 Chi-squared 
p-value
0.0951
G3 Tert-/- AAV9-Tert 5 14 12 7 
G4 Tert-/- AAV9-Tert 5 15 10 7.5 
Percent holes in target quadrant 
Group Number of Mice Total trials 
Trials with performance 
better than corresponding 




WT AAV9-Tert 5 15 3 7.5 Chi-squared 
p-value
0.237
G3 Tert-/- AAV9-Tert 5 14 6 7 
G4 Tert-/- AAV9-Tert 5 15 7 7.5 
Percent time in target quadrant 
Group Number of Mice Total trials 
Trials with performance 
better than corresponding 




WT AAV9-Tert 5 15 4 7.5 Chi-squared 
p-value
0.354
G3 Tert-/- AAV9-Tert 5 14 8 7 
G4 Tert-/- AAV9-Tert 5 15 6 7.5 
Chi-squared tables to calculate statistical significance for the mice after 30 weeks of treatment comparing AAV9-Tert 
treated mice with their corresponding controls of the same treatment age and generation 









































Table 2. Barnes maze chi-squared analysis: comparison of young and old AAV9-null mice 30 weeks 
after treatment. 
Number of holes searched 










WT AAV9-Tert 5 15 12 7.5 Chi-squared 
p-value
0.0541 
G3 Tert-/- AAV9-Tert 4 12 9 6 
G4 Tert-/- AAV9-Tert 5 15 11 7.5 
Time 














G3 Tert-/- AAV9-Tert 4 12 11 6 
G4 Tert-/- AAV9-Tert 5 15 11 7.5 
Path length 










WT AAV9-Tert 5 15 12 7.5 *Chi-squared
p-value
0.0278
G3 Tert-/- AAV9-Tert 4 12 11 6 
G4 Tert-/- AAV9-Tert 5 15 9 7.5 
Percent holes in target quadrant 










WT AAV9-Tert 5 15 12 7.5 Chi-squared 
p-value
0.0807 
G3 Tert-/- AAV9-Tert 4 12 9 6 
G4 Tert-/- AAV9-Tert 5 15 10 7.5 
Percent time in target quadrant 














G3 Tert-/- AAV9-Tert 4 12 12 6 
G4 Tert-/- AAV9-Tert 5 15 12 7.5 
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Preventing accumulation of short telomeres may 
prevent or ameliorate brain aging by allowing stem cells 
to proliferate and regenerate damaged tissue. We have 
previously demonstrated that preventing accumulation 
of short telomeres through telomerase gene therapy can 
ameliorate the symptoms of cardiovascular disease [25], 
pulmonary fibrosis [26], aplastic anemia [24], and aging 
in general [23].  
Thus, to demonstrate that telomere shortening may be 
one of the causes of brain aging, here we studied the 
potential therapeutic effects of a telomerase gene 
therapy in ameliorating molecular signs of neuro-
degeneration associated with physiological mouse aging 
as well as in the context of the telomerase-deficient 
mouse model. There have been many successes for gene 
therapy in the last decade [101–107], and the first gene 
therapy was licensed for human use in Europe in 2012 
(Glybera) [108].  Viral vectors have also been used to 
transduce a wide variety of tissues from liver, skeletal 
muscle, heart, brain, lung, pancreas, to tumors [109]. 
Our findings demonstrate that AAV9-Tert treatment can 
ameliorate signs of neurodegeneration with aging in 
wild-type mice as well as in the context of the 
telomerase-deficient mouse model with the presence of 
short telomeres.  Our treatment was applied through an 
IV tail injection, and therefore, many other cell types 
throughout the body would be infected in addition to the 
cells in the brain.  Improvements of health in other 
organs may have an impact on the brain and invest-
tigating the nature of this relationship could be 
interesting for future studies.  Note also that we did not 
observe any increased incidence of cancer in the mice 
treated with AAV9-Tert, which matched our expecta-
tions since several other articles have demonstrated that 
telomerase reactivation alone does not lead to 
tumorigenesis in vivo [23,39,110,111]. 
Of note, the AAV9 serotype used here to express 
telomerase in the brain primarily transfects neurons and 
astrocytes but fails to transduce microglia [77].  In our 
experimental setting, we found that less than 5% of the 
cells in the brain received the transgene using our vector 
and delivery method.  Interestingly, in spite of the low 
transduction efficiency, we observed significant effects of 
AAV9-Tert gene therapy in decreasing DNA damage, 
increasing neurogenesis as indicated by increased double-
cortin expression, as well as decreasing neuroinflam-
mation (decreased GFAP expression).  These findings 
suggest that even a small number of neurons transduced 
with Tert may increase the health of the environment and 
benefit cells that were not infected, for instance, through 
changing the secretory profile of cells.  In an analogous 
manner, factors found in young blood induce a younger 
phenotype in the recipient cells, as observed from 
parabiosis experiments with young blood [112,113] and 
also treatments with specific factors in young blood such 
as the GDF11 protein [114,115].  Nevertheless, even 
more benefits from telomerase gene therapy may be 
observed if higher transduction efficiencies are obtained.  
MATERIALS AND METHODS 
Mice 
For all the treatment groups, mice were injected IV in 
the tail with 2E12 vg of AAV9 virus particles 
containing the genetic material of interest in a volume 
of 100 μL 0.001% Pluronic F-68 in PBS.   The Pluronic 
F-68 serves as a surfactant to prevent aggregations of
the virus particles from forming [77].  In the experiment
to confirm infection of mouse brain cells, mice were
injected with either AAV9-CMV-eGFP, AAV9-CAG-
eGFP, or AAV9-CMV-Tert.  In the neurodegeneration
aging study, the mice were injected with either AAV9-
Tert or AAV9-null.  The mice were injected at an age of
27-30 weeks. The mice were genetically wild-type or
knockout for telomerase.  Throughout these studies, the
telomerase knockout mice belonged to different
generations: either G1, G2, G3, or G4 Tert-/- genera-
tions. The mouse strain was >95% C57BL/6 back-
ground, and all of the mice used in these experiments
were male.
All mice were produced and housed in the specific 
pathogen-free barrier of the CNIO institution in Madrid 
Spain.  After weaning, five mice were housed per cage 
and fed ad libitum with a non-purified sterilizable 
Teklad 2018 18 percent protein rodent diet (Harlan 
TD.2018S).  All animal procedures were approved by 
the CNIO-ISCIII Ethics Committee for Research and 
Animal Welfare (CEIyBA) and conducted in accor-
dance to the recommendations of the Federation of 
European Laboratory Animal Science Associations.   
MPTP Neurotoxin treatment 
Wild-type or G3 Tert-/- 12-16-week old male mice were 
injected IP with saline or MPTP neurotoxin at a 
concentration of 0.5, 5, 10, or 20 mg/kg body weight. 
Behavior tests such as the footprint test and tail 
suspension test were then performed.  The mice were 
sacrificed in a CO2 chamber 7 days after injection, and 
the brain was preserved in formalin for subsequent 
molecular tests.  
Recombinant AAV vectors 
Vectors were generated by triple transfection of 
HEK293 cells as described previously [116]. Cells were 
cultured in roller bottles (Corning) in DMEM 10% FBS 
to 80% confluence and co-transfected with a plasmid 
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carrying the expression cassette flanked by the AAV2 
viral ITRs, a helper plasmid carrying the AAV rep2 and 
cap9 genes, and a plasmid carrying the adenovirus 
helper functions (kindly provided by K.A. High, 
Children’s Hospital of Philadelphia). The expression 
cassettes used were one of the following: eGFP under 
the control of the CMV promoter, eGFP under the 
control of the CAG promoter, or murine Tert under the 
control of the CMV promoter.  AAV9 vectors were 
purified with an optimized method based on two 
consecutive cesium chloride gradients, dialyzed against 
PBS, filtered, and stored at -80 °C until use [117]. The 
titer of the viral genome particles was determined by 
quantitative real time PCR. 
Confirmation of virus infection and measurement of 
transduction efficiency 
Groups of 8-week old mice were IV tail injected with 
2E12 vg of AAV9 vectors containing different pieces of 
genetic material in 100 μL of 0.001% Pluronic F-68 in 
PBS.  The mouse group size and identity of the injected 
vectors were as follows: 3 mice AAV9-CMV-Tert, 3 
mice AAV9-CMV-eGFP, 2 mice AAV9-CAG-eGFP, 
and 3 control mice receiving no vector.  At 2 weeks 
post-injection, the mice were sacrificed, and IVIS was 
used to measure the fluorescence in the AAV9-CMV-
eGFP mice and controls.  Then half the brain was 
preserved in liquid nitrogen for freezing, and half the 
brain was preserved in formalin for paraffin sections.  
RNA was extracted from frozen tissue, and a qPCR was 
performed to check the level of the Tert and eGFP 
expression.  The paraffin sections were used in an 
immunohistochemistry test for GFP, and for an immu-
nofluorescence experiment for GFP and the microglia 
marker Iba1.  The GFP antibody used in immuno-
histochemistry was mouse monoclonal anti-GFP (Roche 
Cat No 11 814 460 001) as described in more detail in 
the immunohistochemistry section.  The GFP antibody 
used in immunofluorescence was chicken anti-GFP 
(Aves Labs Inc. Cat No GFP-1020), and the Iba1 
antibody used was rabbit anti-Iba1 (Wako Cat No 019-
19741). 
Neurodegeneration aging experiment 
To assess whether AAV9-Tert gene therapy could 
reduce neurodegeneration with age, mice were injected 
with either AAV9-null or AAV9-Tert virus.  The mice 
were injected IV in the tail with 2E12 vg of virus in a 
volume of 100 μL 0.001% Pluronic F-68 in PBS.  The 
mice were injected at an age of 27-30 weeks. The 
cohort consisted of the following mice: 5 wild-type 
AAV9-null, 5 wild-type AAV9-Tert, 4 G3 Tert-/- 
AAV9-null, 5 G3 Tert-/- AAV9-Tert, 5 G4 Tert-/- 
AAV9-null, and 5 G4 Tert-/-AAV9-Tert mice.  After the 
injection, all the mice were allowed to age until the 
humane endpoint.  Behavioral and cognitive tests such 
as the Barnes maze test, object recognition test, rotarod 
test, tightrope test, and tail suspension test were 
performed at various timepoints throughout the lifespan 
of the mice.  At the humane endpoint, the mice were 
sacrificed in a CO2 chamber.  Half of the brain was 
preserved in nitrogen for freezing, and half the brain 
was preserved in formalin for paraffin sections.  The 
paraffin sections cut in a coronal orientation were used 
for q-FISH to measure telomere length, and for 
immunohistochemistry to measure the markers γH2AX, 
doublecortin, and GFAP. 
Telomere Q-FISH analysis of paraffin sections 
Paraffin-embedded tissue sections were hybridized with 
a PNA-telomeric Cy3 probe, and fluorescence intensity 
of telomeres was determined as described previously 
[118,119].  After deparaffinization, tissues were post 
fixed in 4% formaldehyde for 5 min, washed 3X5 min 
in PBS and incubated at 37 °C for 15 min in pepsin 
solution (0.1% Porcine Pepsin, Sigma; 0.01 M HCl, 
Merck).  After repeating another round of washes and 
fixation, slides were dehydrated in a 70%–90%–100% 
ethanol series (5 min each).  After air drying the slides, 
30 μL of telomere probe mix (10 mM TrisCl pH 7, 25 
mM MgCl2, 9 mM citric acid, 82 mM Na2HPO4, 70% 
deionized formamide (Sigma), 0.25% blocking reagent 
(Roche) and 0.5 μg/mL Telomeric PNA probe 
(Panagene)) were added to each slide.  A cover slip was 
applied, and the slides were incubated for 3 min at 85 
°C.  The slides were then incubated 2 hr at room 
temperature in a wet chamber in the dark.  Slides were 
washed 2X15 min in 10 mM TrisCl pH 7, 0.1% BSA in 
70% formamide with shaking, then 3X5 min in TBS 
0.08% Tween 20, and then incubated in a 4 μg/mL 4',6-
diamidino-2-phenylindole DAPI (Sigma) bath in PBS 
before mounting samples in Vectashield (VectorTM). 
Confocal images were acquired as stacks using an SP5-
WLL confocal microscope (Leica) and maximum 
projection images were created using the Fiji version of 
the ImageJ software (NIH) [120,121].  Telomere signal 
intensity was quantified using Definiens Developer Cell 
software (version XD 64 2.5; Definiens AG). 
Immunohistochemistry 
Brains were fixed in 10% neutral buffered formalin with 
4% formaldehyde, paraffin-embedded, cut at 3 µm, 
mounted in Superfrost Plus slides (Thermo Fisher 
Scientific), and dried overnight.  The paraffin brain 
sections were cut in a coronal orientation and a series of 
sections from the posterior part of the brain to the 
anterior part of the brain were placed onto a slide.  For 
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different staining methods, slides were deparaffinized in 
xylene and re-hydrated through a series of graded 
ethanol washes until a final wash with water. 
Consecutive sections were stained with an automated 
Ventana Discovery XT immunostaining platform 
(Roche).  Antigen retrieval was first performed with 
high pH CC1m buffer (Roche) and endogenous pero-
xidase was blocked with 3% hydrogen peroxide.  Next 
the slides were incubated with one of the following 
primary antibodies: pre-diluted rabbit monoclonal SP6 
anti-Ki67 (Master Diagnostica Cat No 000311OQD), 
mouse monoclonal JBV301 anti-γH2AX at a 1/25,000 
dilution (Millipore Cat No 05-636), mouse monoclonal 
7.1+13.1 anti-GFP at a 1/500 dilution (Roche Cat No 
11.814.460.001), rabbit polyclonal anti-doublecortin at 
a 1/500 dilution (Abcam Cat No ab18723), rabbit 
polyclonal anti-glial fibrillary acidic protein (GFAP) at 
a 1/750 dilution (DAKO Z0334), or rabbit monoclonal 
anti-tau (phospho S396) at a 1/2000 dilution (Abcam 
Cat No ab10930).  After the primary antibody step, 
slides were incubated with either the rabbit anti-mouse 
secondary antibody (Epitomics) or the OmniMap anti-
rabbit detection system (Ventana Roche) conjugated 
with horseradish peroxidase.  The immunohisto-
chemistry (IHC) reaction was developed using 
ChromoMap 3,3'-Diaminobenzidine tetrahydrochloride 
DAB (Ventana Roche) and nuclei were counterstained 
with Carazzi’s hematoxylin.  Finally, the slides were 
dehydrated, cleared, and mounted with a permanent 
mounting medium for microscopic evaluation.  Positive 
control sections known to be positive for the primary 
antibody were included for each staining procedure.  
Images of whole slides were acquired with an AxioScan 
Z1 slide scanner (Zeiss) and visually checked with the 
Zen Blue software (Zeiss).  The digital images from the 
scan were then quantified by counting the number of 
positive cells in different fields of view.  Either Zen 
Blue software (Zeiss) or the Fiji version of the ImageJ 
software (NIH) [120,121] was used for this quan-
tification. 
Immunofluorescence 
For immunofluorescence (IF), the slides were first 
prepared and antigen retrieval was performed as 
described previously in the immunohistochemistry 
section.  Next the slides were washed 2X5 min in PBS.  
The slides were then permeabilized in 0.5% Triton X-
100 in PBS for 3 hr at room temperature (RT), washed 5 
min in 1X PBS, blocked with fetal bovine serum (FBS) 
for 2 hr, and then the slides were incubated with 
primary antibody overnight at 4 °C in a humidity 
chamber.  The primary antibodies used were one of the 
following: rabbit polyclonal anti-tyrosine hydroxylase 
(Millipore Cat No AB152), chicken anti-GFP (Aves 
Labs Inc. Cat No GFP-1020), or rabbit anti-Iba1 (Wako 
Cat No 019-19741).  Next the slides were washed 4X7 
min with 1XPBS 0.1% Tween 20 at RT, washed with 
1XPBS 5 min, and incubated with secondary antibody 1 
hr at RT in a humidity chamber.  The secondary 
antibodies used were one of the following: goat anti-
rabbit Cy3 (Jackson Cat No 4134) or goat anti-chicken 
AF488 (Life Technologies Cat No A11039).  Next the 
slides were washed 3X10 min with PBS, incubated with 
DAPI 5 min at RT, washed 5 min with PBS, 30 μL of 
Vectashield (VectorTM) was added, and the slides were 
sealed with nail polish.  Confocal images were acquired 
as stacks using an SP5-WLL confocal microscope 
(Leica) and maximum projection images were created 
using the Fiji version of the ImageJ software (NIH) 
[120,121].  Fluorescence intensity was quantified using 
Definiens Developer Cell software (version XD 64 2.5; 
Definiens AG). 
Quantitative real-time PCR 
Total RNA from nitrogen frozen tissues was extracted 
with Qiagen’s RNeasy mini kit (Qiagen Cat No 74106), 
according to the manufacturer’s instructions.  Before 
processing, RNA samples were DNaseI treated using 
the RNase-free DNase Set (Qiagen Cat No 79254) 
according to the manufacturer’s instructions.  First-
strand cDNA was synthesized from this RNA using an 
iScript cDNA synthesis kit (Bio-RAD Laboratories, Inc. 
Cat No 1708891) according to the manufacturer’s 
instructions.  The reaction consisted of 15 μL of 1 μg 
RNA, 4 μL of 5X iScript reaction mix, and 1 μL iScript 
reverse transcriptase.  A Primus 96 Plus thermocycle 
instrument was used with the following settings: 5 min 
25 °C; 30 min 42 °C; 5 min 85 °C; 4 °C hold.  The PCR 
reactions were performed using the GoTaq qPCR 
Master Mix (Promega Cat No A6002) according to the 
manufacturer’s instructions.  The reaction mix consisted 
of 6 μL GoTaq PCR master mix, 0.2 μL 10 uM forward 
primer, 0.2 μL 10 μM reverse primer, 2 μL of 1/10 
dilution of first-strand cDNA, and 3.6 μL H20. 
Quantitative real-time PCR was performed for these 
reactions using an ABI PRISM 7700 384 well plate 
reader (Applied Biosystems) according to the manu-
facturer’s instructions.  The thermocycle program was 
as follows: Hold stage (1.6 °C/s ramp; 50 °C 2 min; 1.6 
°C/s ramp; 95 °C 10 min); PCR Stage with 40 cycles 
(95 °C 0:15 min; 1.6 °C/s ramp; 60 °C 1 min; 1.6 °C/s 
ramp; 68 °C 1 min); Melt Curve Stage (1.6 °C/s ramp; 
95 °C 0:15 min; 1.6 °C/s ramp; 60 °C 1 min; 0.05 °C/s 
ramp; 95 °C 0:15 min).  The following primers were 











GAPDHRev:          5’-AGACGGCCGCATCTTCTT-3’. 
Micro PET imaging 
Images were acquired using an eXplore Vista PET-CT 
instrument (GE Healthcare).  Mice were injected with 
15 MBq (megabecquerel) of 18F-FDG (ITP 
Cyclotron) into the lateral tail vein in a volume of 0.1 
cc. During imaging, mice were anaesthetized with a
continuous flow of 1% to 3% isoflurane/oxygen
mixture (2 L/min) 45 min after radiotracer injection.
MicroPET scans were performed for 20 min per bed.
Only one mouse was used per bed.  PET images were
reconstructed with a three-dimensional Ordered Subsets
Expectation-Maximization (OSEM) reconstruction
algorithm and were analyzed using MMWS software
(eXplore Vista, GEHC) [122].  The images were
analyzed by drawing a region of interest (ROI) and
calculating the 18F-FDG SUV (standardized uptake
value) using the following formula: SUV = Tissue
concentration ROI activity (Mbq/ml) / (Injected dose
(Mbq) / Body weight (g)).
IVIS 
The fluorescence intensity of the mice was measured 
immediately after sacrifice in a CO2 chamber.  An IVIS 
Spectrum (Xenogen) instrument was used to measure 
fluorescence, and the Living Image version 4.3.1 
(Caliper Life Sciences, Inc.) software was used for 
quantification.  The fluorescence intensity was dis-
played with log scale and rainbow coloring with a min 
value of 511 and a max value of 1205.  The fluo-
rescence intensity of the desired region of interest (ROI) 
was then quantified. 
Behavioral and cognitive tests 
Several behavioral and cognitive tests were performed 
with the mice to measure health.  The rotarod test was 
used to evaluate motor coordination and balance in mice 
[123].  The mice were tested in a rotarod apparatus 
(Panlab model LE 8200) using a continuous 
acceleration protocol from 4 to 40 rpm in a period of 
120 s.  The time before the mice fell was recorded, and 
the average of three trials was used in the quantification.  
In the tightrope test [124,125], the mice were placed 
onto a rod (“the tightrope”) for 5 trials for 60 s.  Each 
trial that the mouse did not fall was counted as a 
success, and the percent success for each mouse was 
determined.   
The object recognition test measures the ability of 
mice to remember objects in their environment and 
provides an index of recognition memory [72,126].  
The mice were first presented with two identical 
objects for 10 min.  Then after 24 hours, the mice were 
presented with one object that was identical to the 
previous objects and one novel object.  The amount of 
time the mouse spent investigating the new object by 
sniffing or touching the new object indicated that the 
mouse may have recognized that this object was new. 
The final results were presented as the ratio of time the 
mouse spent investigating the new object to the total 
time investigating both objects. 
The tail suspension test evaluates psychological 
depression, motivation, and energy levels in mice by 
measuring the amount of time the mice spend trying to 
escape by struggling and moving when hung from their 
tail [70].  Mice typically struggle less and move less 
with old age.  Video recordings were captured for each 
mouse, and the amount of movement was then 
quantified.  More movement indicates less depression, 
more motivation, and higher energy levels.  The mice 
were hung by the tail using a length of tape of 
approximately 17 cm.  A plastic tube cut from a 10 mL 
pipette was placed around the tail before attaching the 
tape in order to prevent the mice from climbing their 
own tails during the test.  Videos of the mice were 
captured using a standard PowerShot SX430 camera 
(Canon) held stable by a STAR 75 tripod (Hama). 
Analysis of the video was performed by first converting 
the video into a sequence of images using the VLC 
VideoLAN Client (VideoLAN Organization) [127].  
This image sequence was then analyzed with the Fiji 
version of the ImageJ software (NIH) [120,121].  
Briefly, the color was inverted so that the white tape 
became black and the black background became white, 
a z-projection of the average intensity was created to 
identify where the mouse was located the majority of 
the time throughout the video sequence, a rectangular 
region of interest (ROI) was created around the region 
of tape close to the mouse, the ROI was restored onto 
the original image sequence (instead of the single frame 
z-projection), the integrated intensity of the ROI in each 
image was measured and output to a spreadsheet, and 
the number of image frames in which the integrated 
density was greater than the threshold was determined. 
These frames indicate that the mouse was moving since 
more white background is detected in these frames 
instead of the black tape which would be in the frame if 
the mouse was not moving.  The amount of time that the 
mouse was immobile was then displayed in a bar graph. 
This method of analysis correctly yielded long 
immobility times for mice which moved very little, and 
short immobility times for mice that were moving 
frequently. 
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The footprint test measures the stride length of the mice 
and has been used to quantify mobility in Parkinson’s-
like mouse models [128,129].  The paws of the mice 
were painted with watercolor paint.  The front and hind 
limbs were painted with a different color.  The mice 
were then placed into a hallway with paper on the floor.  
The hallway was 8 cm wide and 60 cm long.  The mice 
then moved through the hallway into a dark container at 
the end which they could hide in.  Three trials were 
performed with each mouse, and the distance between 
the footprint paint marks on the paper was then 
measured with a ruler.  The hind paw stride length was 
the average of the lengths for both the right and left 
paws, and the front paw stride length was measured in 
the same manner. 
The Barnes maze test is used to evaluate the learning 
ability and spatial memory of mice [130–132].  The 
mice are trained to find a hole leading to an escape box 
on a table with many other holes.  Visual cues such as 
simple colored shapes around the room and normal 
objects in the room were used so that the mice could 
orient themselves on the table.  The training consisted 
of a habituation day in which the mice were guided to 
the target box with a glass beaker from the center of the 
table, the first training day in which the mice were 
allowed to explore the table for 3 trials for 2 min, a 
second training day in which the mice were allowed to 
explore the table for 2 trials for 2 min, a resting day, and 
then the final test day in which 3 trials of 2 min were 
performed.  Aversive stimuli such as a bright light 
above the table from a flashlight and a digital 
metronome (Seiko Cat No DM50SE) which makes a 
repetitive loud noise set at 132 bpm were used to 
motivate the mouse to search for and escape into the 
goal box.  The wide-open space on the table also serves 
as an aversive stimulus since the mice are exposed to 
any threat.  Note that the Barnes maze test is often 
considered to be more humane than the Morris water 
maze.  The final output of the test was represented as 
the time the mice took to find the target box, the path 
length, the number of holes searched, the number of 
holes searched in the target quadrant of the table, and 
the time spent in the target quadrant of the table. 
Performance on this test is related to the health of the 
hippocampus which  is responsible  for spatial  memory. 
Videos of the Barnes maze test trials were analyzed to 
quantify the results.  The maintenance facility of the 
CNIO constructed a goal post-like structure, and a 
standard PowerShot SX430 camera (Canon) was 
attached to the top of this structure with a screw above 
the table to video record the tests.  To determine the 
time required for each mouse to find the goal box, and 
to determine the hole ids visited before finding the goal 
box, the videos were simply watched, and the in-
formation was recorded.  Note that the time recorded 
refers to the time for the mouse to first find the goal box 
hole (approach the hole and look into it), not actually 
enter the hole into the goal box.  Sometimes the mice 
would find the hole, and then wait a considerable 
amount of time before actually entering the hole.  The 
videos were watched with the SMPlayer media player 
(https://www.smplayer.info/) so that we could play the 
videos forward or backward frame by frame and at 
custom speeds such as twice the speed to assist with the 
analysis.  The SMPlayer window was also made 
transparent and placed over a diagram of the table with 
ID numbers for each hole made in the Inkscape vector 
graphics editor (https://inkscape.org).  To determine 
other variables such as path length, and the percent time 
in the target quadrant, each video was first converted 
into an image sequence using the VLC VideoLAN 
Client (VideoLAN Organization) [127].  The image 
sequence was imported into the Fiji version of the 
ImageJ software (NIH) [120,121], and analyzed. 
Briefly, regions of interest (ROIs) for the quadrants 
were created.  Any part of the image scene which was 
very dark was cleared so that the black mouse was the 
darkest object in the image.  The min value in each 
quadrant for each frame was then measured.  Frames 
with a min value below a certain threshold were frames 
which contained the mouse, and the percent time the 
mouse spent in each quadrant was determined.  To 
quantify the path length, the brightness of the image 
was increased to the max value, the contrast was 
increased until most of the artifacts in the image 
disappeared and only the mouse could be seen.  A thres-
hold was applied to the image so that only pure white 
and black colors remained.  Then the MTrack2 plugin 
[133] for Fiji was used to track the movement of the
mouse, quantify the path length, and also produce a
trace image of the path taken by the mouse.  The
parameters necessary for the plugin would vary
depending on the conditions of the video, but in our
videos the following parameters usually produced
correct path tracings: Min Particle Size: 300, Max
Particle Size: 10,000, Max Speed: 10,000, and
Minimum Track Length (frames): 5.  The resulting
variables of "number of holes searched", "path length",
"time", "percent time in target quadrant", and "percent
holes in target quadrant" were then graphed.
Statistical and mathematical analyses 
An unpaired Student’s t-test was used to compare the 
groups of mice for the brain weights, brain area, 
telomere spot fluorescence, histopathology, immuno-
fluorescence, PCR, footprint test, tightrope test, rotarod 
test, tail suspension test, object recognition test, and 
PET test results since each individual mouse cannot 
belong to more than one group and the variables are 
assumed to be normally distributed.  A χ2 (chi-squared) 
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test was used for the Barnes maze test to determine 
whether AAV9-Tert treated groups performed better 
than their corresponding AAV9-null controls with a 
matching generation.  This test was implemented since 
we were comparing categorical variables, specifically 
whether a mouse performed better or worse than the 
AAV9-null group of the same generation.  For statis-
tical tests and mathematical analysis, we used the Excel 
2016 software (Microsoft). 
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Figure S1.  Younger mice and wild-type mice have more doublecortin in the cerebral cortex than older and G3 Tert-/- mice 
and more neurogenic niches in the parietal subventricular zone. (A) Percent doublecortin in parietotemporal region of cerebral 
cortex. (B) Percent doublecortin in occipital region of cerebral cortex. (C) The level of neurogenic niches in the parietal subventricular zone 
quantified from hematoxylin and eosin stained paraffin sections.  
 


















































































































Figure S2.  Mice deficient for telomerase are more susceptible to Parkinson’s-like symptoms induced by MPTP 
neurotoxin. (A) Scheme of the MPTP neurotoxin experiment.  Wild-type or G3 Tert-/- mice, were injected with different doses of MPTP 
or saline solution.  Behavior tests were performed, and the mice were sacrificed 7 days after injection.  The brain was preserved in 
formalin. (B)  Hind paw stride length from footprint test.  (C)  The immobility time in the tail suspension test. (D) Immunofluorescence 
results for tyrosine hydroxylase in the substantia nigra for mice treated with different doses of MPTP neurotoxin. (E) Immuno-
fluorescence results for tyrosine hydroxylase in the substantia nigra for young and old wild-type and G3 Tert-/- mice.  Data represent the 
mean ±SE of analyzed mice within each group. For the histopathology results, the number of mice analyzed per group is indicated, as well 
as the number of fields of view, and the number of positive cells. The t-test was used for statistical analysis. *p<0.05; **p<0.01; 
***p<0.001.  
 


















































































































Figure S3. Mice deficient for telomerase perform more poorly in the tightrope test, rotarod test, tail suspension test, 
and object recognition test, and they also have less glucose uptake in the brain.  (A) Percent success in the tightrope test for 
wild-type and Tert-/- mice at 70-90 weeks of age.  (B) Time in rotarod test for wild-type, G2 Tert-/-, and G4 Tert-/- mice at 70-100 weeks 
of age.  (C) Immobility time in tail suspension test for old wild-type, G2 Tert-/-, G3 Tert-/-, and G4 Tert-/- mice.  (D) Ratio of time spent 
investigating a novel object (Time B) to the time spent investigating both objects (Time A+B) in the object recognition test.  (E) Standard 
uptake value (SUV) of 18F-FDG (18F-fluorodeoxyglucose) into the brain in a positron emission tomography (PET) test. Representative 
heatmaps displaying the quantity of glucose uptake are also shown.  Data represent the mean ±SE of analyzed mice within each group. 
The number of mice analyzed per group is indicated. The t-test was used for statistical analysis. *p<0.05; **p<0.01. 
 


























































Figure S4. Body weights of the mice treated with AAV9-Tert or AAV9-null.  These weights were determined 
at the humane endpoint.  The age of death, the weeks of treatment, and the generation for each group is presented. 
